Abstract
Quinapril HCl is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor ofACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).ATIIregulates blood pressure and is a key component of the Renin-Angiotensin-Aldosterone System (RAAS). Quinapril hcl has a short biological half-life of 2 hrs with a prolonged terminal phase of 25 hours. So the floating tablet formulations are needed for Quinapril hcl to prolong its duration of action, to increase its oral bioavailability and to improve patient compliance. Many methods are used for preparing floating tablet preparations of Quinapril hcl by using various grades of Hydroxypropyl methyl celluloses (HPMC K4M, K15M, K100M) at various concentrations 10%, 20% and 30%. This review article comprises of the research materialized in the field of formulation and evaluation of floating tablets of Quinapril HCl.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
